Our image makes strong claims that Free T3, not TSH, needs to become the main target in thyroid therapy. It is based on three scientific articles in 2015, 2016, and 2018 by a team of four thyroid researchers. I summarize and quote them here. (1) “My free T3 is at risk” This research reveals the human body prioritizes the protection of FT3 levels. The healthy body does so by stimulating the thyroid gland to keep bloodstream FT3 levels steady. However, in T4 monotherapy, Free T3 levels become destabilized. Therefore, the standard thyroid therapy is unable to regulate FT3 levels like …
Month: March 2019
Review: Chronic fatigue syndrome and Low T3
Ruiz-Núñez et al’s 2018 article, “Higher Prevalence of “Low T3 Syndrome in Patients With Chronic Fatigue Syndrome,” breaks down the common misconception that Low T3 syndrome only occurs in critical illness. Low T3 can also occur in a chronic state during chronic illness. A more extreme state of free T3 below reference range occurred in 16% (16 out of 98) Chronic Fatigue Syndrome (CFS) patients versus 7% (7 out of 99) controls, yielding an odds ratio of 2.56 for having low Free T3 in CFS. Many of the CFS patients’ thyroid hormone levels and TSH were similar to those seen …
Biondi and Wartofsky’s 2014 dismissal of desiccated thyroid
Bernadette Biondi and Leonard Wartofsky’s article in 2014 titled “Treatment with Thyroid Hormone” summarily dismisses the use of desiccated thyroid medication in thyroid therapy. Tracing the logic of their dismissal back to their citation, a 1980 research article, reveals a fallacious chain of argument based on a very thin foundation. This pathway of reasoning promotes mistaken assumptions and long-standing medical biases against this alternative mode of thyroid therapy. These biases are largely founded on the fear of the unknown and the unwillingness to carefully investigate the reasons why desiccated thyroid therapy can often yield no signs or symptoms of hyperthyroidism …